MedPAC recommends Congress target rebate traps, biosimilars to bring down drug prices
Congress should focus its efforts to reduce drug costs around making changes to Medicare Parts B and D, reducing reinsurance rates and improving biosimilar availability, the Medicare Payment Advisory Commission (MedPAC) said during its meeting on Friday.
